Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S70-S76
DOI: 10.4103/ijmpo.ijmpo_141_17
Original Article

Demographic and Clinical Characteristics of Chronic Myeloid Leukemia Patients: A Study on Confined Populations of Southern India

Manjula Gorre
Departments of Biochemistry, University College of Science, Osmania University, Hyderabad, Telangana, India
,
RB Sashidhar
Departments of Biochemistry, University College of Science, Osmania University, Hyderabad, Telangana, India
,
Sandhya Annamaneni
Departments of Genetics, University College of Science, Osmania University, Hyderabad, Telangana, India
,
Raghunadharao Digumarti
Departments of Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
,
Vishnupriya Satti
Departments of Genetics, University College of Science, Osmania University, Hyderabad, Telangana, India
› Author Affiliations Financial support and sponsorship This work was supported by the UGC-Dr. DS. Kothari Post Doctoral Fellowship Program to Dr. Manjula Gorre (F.4-2/2006 [BSR]/BL/14-15/0150).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Context: Chronic myeloid leukemia (CML) is one of the most common hematological malignancies in all populations throughout the world. Even though the pathophysiology of CML was well explained in majority of the studies, the incidence of CML was shown to exhibit population diversity, and hence, the demographic factors underlying CML origin remain to be understood. Further, the introduction of tyrosine kinase inhibitors had revolutionized the treatment of CML over the years; however, there is a need for developing tailoring therapy to individual risk since the patient clinical heterogeneity poses a major problem during drug response. Therefore, the study of basic clinical picture may aid in planning treatment strategies for CML patients. Aim: The aim of this article is to study the epidemiological and clinical variables associated with the prognosis of CML. Subjects and Methods: We have considered the distribution of various demographic and clinical variables among 476 CML patients diagnosed at Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India. Statistical Analysis Used: All the analyses were performed through SPSS software (version 21.0). Correlation and Cox regression analyses were also performed. Results: Apart from the elevated male sex ratio in CML incidence, high frequency of males was observed to be nonresponders to imatinib mesylate (IM). IM response was shown to be dependent on phase of diagnosis, whereas overall survival of CML patients depends on the age at onset and response to IM. Conclusions: The study of epidemiology and clinical picture of CML patients may help in planning better treatment strategies at diagnosis to achieve long-term progression-free survival.

Keywords

Chronic myeloid leukemia - clinical variable - epidemiology - imatinib mesylate - survival


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009; 22: 295-302
    CrossrefPubMedGoogle Scholar
  • 2 Leitner AA, Hehlmann R. Modern therapy of chronic myeloid leukemia: An example for paradigma shift in hemato-oncology. Internist (Berl) 2011; 52: 209-17
    CrossrefPubMedGoogle Scholar
  • 3 National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available from: https://www.seer.cancer.gov. [Last accessed on 2014 Sep 15].
    Google Scholar
  • 4 American Cancer Society. Cancer Facts & Figures. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html. [Last accessed on 2016].
    Google Scholar
  • 5 Cortes JE, Richard TS, Hagop K. Chronic myelogenous leukemia. In: Padzur R, Coia LR, Hoskins WJ, Wagman LD. editors Cancer Management: A Multidisciplinary Approach. 10th ed. Lawrence: CMPMedica; 2007: 789
    Google Scholar
  • 6 Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE. et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789-99
    CrossrefPubMedGoogle Scholar
  • 7 Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC. et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon Alfa. Writing committee for the Collaborative CML prognostic factors project group. J Natl Cancer Inst 1998; 90: 850-8
    CrossrefPubMedGoogle Scholar
  • 8 Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011; 118: 686-92
    PubMedGoogle Scholar
  • 9 Sokal BR. Hasford and EUTOS Score Calculator. Prognostic Scores for Chronic‑Phase Chronic Myeloid Leukemia. Available from: http://www.bloodref.com/myeloid/cml/sokal-hasford.
  • 10 Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW. et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009; 89: 14-23
    CrossrefPubMedGoogle Scholar
  • 11 National Cancer Registry Programme. Two year report of the population based cancer registries 1999-2000. New Delhi: Indian Council of Medical Research; 2005
    Google Scholar
  • 12 Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 2013; 34: 154-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Robert AW. The Biology of Cancer. Garland Science; 2006
    Google Scholar
  • 14 Malhotra P, Varma N, Varma S. A short report on chronic myeloid leukemia from post graduate institute of medical education and research, Chandigarh. Indian J Med Paediatr Oncol 2013; 34: 186-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K. et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 2013; 179: 361-82
    CrossrefPubMedGoogle Scholar
  • 16 Lee SJ. Chronic myelogenous leukaemia. Br J Haematol 2000; 111: 993-1009
    PubMedGoogle Scholar
  • 17 Mc Guire TR, Kazakoff PW. Pharmacotherapy. A Pathophysiologic Approach. 4th ed. USA: Elsevier NY; 1999
    Google Scholar
  • 18 Vojdani A, Ghoneum M, Brautbar N. Immune alteration associated with exposure to toxic chemicals. Toxicol Ind Health 1992; 8: 239-54
    CrossrefPubMedGoogle Scholar
  • 19 Whitney KD, Seidler FJ, Slotkin TA. Developmental neurotoxicity of chlorpyrifos: Cellular mechanisms. Toxicol Appl Pharmacol 1995; 134: 53-62
    CrossrefPubMedGoogle Scholar
  • 20 Moser VC. Dose-response and time-course of neurobehavioral changes following oral chlorpyrifos in rats of different ages. Neurotoxicol Teratol 2000; 22: 713-23
    CrossrefPubMedGoogle Scholar
  • 21 Texas Oncology. Available from: https://www.texasoncology.com/news-releases/2013/new-blood-cancer-outpatient-treatment-clinic-opene.
  • 22 Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hollenbeck AR. et al. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2013; 22: 848-54
    CrossrefPubMedGoogle Scholar
  • 23 Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. et al. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol 2013; 37: 410-6
    CrossrefPubMedGoogle Scholar
  • 24 Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A. et al. Gender aspects in chronic myeloid leukemia: Long-term results from randomized studies. Leukemia 2005; 19: 984-9
    CrossrefPubMedGoogle Scholar
  • 25 Kumar L. Chronic myelogenous leukaemia (CML): An update. Natl Med J India 2006; 19: 255-63
    PubMedGoogle Scholar
  • 25a Annual Report and Accounts Cancer Research UK; 2012-2013. Available from: http://www.cancerresearchuk.org/sites/default/files/cruk_annual_report_2012_13.pdf.
  • 26 Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN. et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 2010; 123: 764.e1-9
    Google Scholar
  • 27 Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol 2013; 52: 837-41
    CrossrefPubMedGoogle Scholar
  • 28 Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48-56
    CrossrefPubMedGoogle Scholar